tiprankstipranks
Jasper Therapeutics Board Changes and New Director’s Arrival
Company Announcements

Jasper Therapeutics Board Changes and New Director’s Arrival

Don't Miss Our Christmas Offers:

Jasper Therapeutics (JSPR) has provided an update.

Anna French, D.Phil., resigned from the Board of Directors at Jasper Therapeutics, Inc., with no disputes cited, and was succeeded by Svetlana Lucas, Ph.D., on June 18, 2024. Dr. Lucas brings extensive experience in biopharmaceuticals, having held roles at Scribe Therapeutics, Tizona Therapeutics, and Amgen. She has been granted an option to purchase shares and will receive standard compensation for her directorship. Her appointment, free from any insider relationships or reportable transactions, was publicly announced by the company.

For detailed information about JSPR stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyJasper Therapeutics initiated with an Outperform at BMO Capital
TheFlyJasper: First patient dosed in ETESIAN clinical study of briquilimab in asthma
TipRanks Auto-Generated NewsdeskJasper Therapeutics Advances in Antibody Therapy Development
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App